WebBackground: The dual orexin receptor antagonist ACT-541468 showed sedative pharmacodynamic effects during initial clinical testing in adult subjects. The present … WebDaridorexant 通过阻断食欲素的活动来减少与失眠相关的过度清醒。,Daridorexant ; ACT541468 ; ACT 541468 ; ACT-541468. 武汉永璨生物科技有限公司 +86-27-65522453 …
イドルシア 不眠症治療薬・ダリドレキサント 23年上半期に承認 …
WebJul 16, 2024 · 肝癌、原发性胆汁性肝硬化或任何形式的胆汁淤积性疾病。. 使用可能干扰 ACT-541468 PK 的药物(中度至强 CYP3A4 抑制剂或诱导剂)。. 研究者认为可能影响完全参与研究或遵守方案的任何情况或条件。. 健康受试者的附加排除标准(A 组). 任何不稳定疾病的病史或 ... WebApr 8, 2024 · Double-blind to the administration of ACT-541468 (participant). Single- and double-blind to the administration of ACT-541468 (Investigator, single-/double blind is dependent on treatment arm team). Single-blind study with the inclusion of two double-blind nested crossover parts, i.e., subjects will remain blinded to all administrations of ACT ... green cross acsie
Clinical pharmacology of the dual orexin receptor antagonist ACT …
WebApr 5, 2024 · A Single-center, Double-blind, Placebo-controlled, Randomized Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single- … Web(act-541468)の用量反応を確認 日本での承認取得に向けた検証的試験の準備を進める アルシュビル、スイスおよび東京、日本―2024 年8 WebOct 26, 2024 · A study in healthy male subjects to investigate whether administration of ACT-541468 can affect the fate in the body (amount and time of presence in the blood)...。治験登録。 ICH GCP。 greencross alabang